Hemophilia A Market Growth Driven by Novel Therapies and Gene Therapy

The hemophilia A market landscape is set for transformation, fueled by rising disease prevalence and the introduction of innovative therapies like Mim8 (Novo Nordisk), DTX201 (Pebocotocogene camaparvovec, BAY2599023 [Ultragenyx Pharmaceutical]), giroctocogene fitelparvovec (SB-525 [Sangamo Therapeutics]), and more during the forecast period.

LAS VEGAS, Dec. 3, 2025 /PRNewswire/ -- DelveInsight's Hemophilia A Market Insights report offers deep insights into current treatment practices, emerging hemophilia A drugs, therapy market shares, and market size projections from 2020 to 2034 across key markets: the United States, EU4 (Germany, France, Italy, Spain), UK, and Japan.

Hemophilia A Market Summary The hemophilia A market reached USD 12.2 billion in the 7MM in 2024. The US dominated with ~48% of the total 7MM market share in 2024, outpacing EU4, UK, and Japan. HEMLIBRA's US Q1 2025 YoY sales growth flattened, signaling rising competition from new entrants. Diagnosed prevalent cases of hemophilia A in the 7MM totaled ~49,500 in 2024. Key players like Novo Nordisk, Ultragenyx Pharmaceutical, Sangamo Therapeutics, ASC Therapeutics, Roche, Chugai, and others are advancing novel hemophilia A therapies. Pipeline highlights include Mim8, DTX201 (Peboctocogene camaparvovec, BAY2599023), Giroctocogene fitelparvovec (SB-525), ASC618, NXT007/RG6512, and others.

Discover the new hemophilia A treatment @ Hemophilia A Treatment Market

Key Growth Drivers for the Hemophilia A Market Expanding Patient Pool Diagnosed hemophilia A prevalence is projected to grow from 49K cases in 2024 to 50K by 2034, driven by better diagnostics and heightened awareness.

Gene Therapy Breakthroughs Gene therapies are revolutionizing care. BioMarin's ROCTAVIAN, approved in the US and EU, delivers one-time Factor VIII correction. Pfizer's giroctocogene fitelparvovec showed superior bleed reduction in late-stage trials versus standard therapies.

Regulatory Wins Fueling Expansion FDA approved Pfizer's HYMPAVZI (Oct 2024) – once-weekly subcutaneous for hemophilia A patients ≥12 years. Sanofi's QFITLIA (Mar 2025) – bi-monthly subcutaneous option for hemophilia A/B patients ≥12 years.

Rise of Non-Factor Therapies Innovations include anti-TFPI agents (Pfizer's HYMPAVZI, Novo Nordisk's ALHEMO) and siRNA therapies (Sanofi's QFITLIA).

Vibrant Clinical Pipeline Active development by Novo Nordisk (Mim8, ALHEMO), Sangamo (Giroctocogene fitelparvovec), Roche/Chugai (NXT007), ASC Therapeutics (ASC-618), Ultragenyx (DTX201), and others.

Hemophilia A Market Analysis Current strategies focus on preventing bleeding complications via on-demand or prophylactic regimens, with prophylaxis gaining favor. Approved recombinant Factor VIII options include HELIXATE FS, ADVATE, ELOCTATE, JIVI, and more. Plasma-derived products like HEMOFIL M persist.

Newer entrants: QFITLIA (fitusiran) – siRNA therapy reducing antithrombin for enhanced clotting (6 doses/year, suitable for inhibitor/non-inhibitor patients).

HEMLIBRA leads prophylaxis for inhibitor patients, complementing immune tolerance induction (ITI).

Future shifts: extended half-life factors, siRNA, bispecific antibodies, and gene therapies will intensify competition.

Hemophilia A Competitive Landscape Mid- to late-stage pipeline stars: Mim8 (Novo Nordisk) – subcutaneous bispecific antibody mimicking FVIIIa for weekly/monthly dosing. DTX201 (Ultragenyx) – AAVhu37-based gene therapy for sustained liver-targeted FVIII expression.

These launches will redefine standards, driving innovation and market growth.

Discover more about the FDA approved gene therapy hemophilia A @ FDA Approved AAV Gene Therapy Hemophilia A

Recent Developments Jul 2025: Novo Nordisk's ALHEMO FDA-approved for once-daily prophylaxis in hemophilia A/B (≥12 years, no inhibitors), expanding from prior inhibitor indication. Jun 2025: Pfizer's Phase 3 BASIS trial success for HYMPAVZI in hemophilia A/B with inhibitors. May 2025: FDA nods Jivi (Bayer) for pediatric hemophilia A (≥7 years) based on PROTECT trials. Mar 2025: Alnylam's Qfitlia™ (fitusiran) approved – first AT-lowering RNAi therapy for bleeds.

Hemophilia A Market in Japan and Asian Clinical Development Japan leads Asia in Hemophilia A clinical development, primarily driven by Chugai Pharmaceutical Co., Ltd. Hemophilia A therapies include HEMLIBRA® (emicizumab), a bispecific antibody bridging activated factor IXa and factor X to mimic factor VIII, approved in Japan and Taiwan with ongoing Phase III studies for acquired Hemophilia A. Chugai’s next-generation agent NXT007, a bispecific FVIII mimetic, is in Phase I/II (NXTAGE trials, jRCT2080224835, NCT05987449) with Phase III planned for 2026, showing favorable hemostatic activity and tolerability, including transitions from emicizumab. Korean and Taiwanese companies currently have no locally sponsored Phase 1–3 Hemophilia A trials, though both markets use approved global therapies.

What is Hemophilia A? Hemophilia A is a genetic bleeding disorder from Factor VIII deficiency. Evolution from plasma-derived to recombinant FVIII has improved outcomes. Typically congenital, it can be acquired via factor-neutralizing antibodies.

Hemophilia A Epidemiology In 2024, the US led 7MM diagnosed prevalent cases at ~14,900, with steady increases expected.

Related report

Hemophilia A - Epidemiology Forecast - 2034

DelveInsight’s ‘Hemophilia A – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan. The leading Hemophilia A Companies developing therapies include - BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.

Hemophilia A - Pipeline Insight, 2026

DelveInsight’s, “Hemophilia A - Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Hemophilia A pipeline landscape. The leading Hemophilia A Companies developing therapies include - BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com